Suppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumors.

UNLABELLED Invasion and metastasis increase after the inhibition of VEGF signaling in some preclinical tumor models. In the present study we asked whether selective VEGF inhibition is sufficient to increase invasion and metastasis and whether selective c-Met inhibition is sufficient to block this effect. Treatment of pancreatic neuroendocrine tumors in RIP-Tag2 mice with a neutralizing anti-VEGF antibody reduced tumor burden but increased tumor hypoxia, hypoxia-inducible factor-1α, and c-Met activation and also increased invasion and metastasis. However, invasion and metastasis were reduced by concurrent inhibition of c-Met by PF-04217903 or PF-02341066 (crizotinib). A similar benefit was found in orthotopic Panc-1 pancreatic carcinomas treated with sunitinib plus PF-04217903 and in RIP-Tag2 tumors treated with XL184 (cabozantinib), which simultaneously blocks VEGF and c-Met signaling. These findings document that invasion and metastasis are promoted by selective inhibition of VEGF signaling and can be reduced by the concurrent inhibition of c-Met. SIGNIFICANCE This report examines the mechanism of increased tumor aggressiveness after anti-VEGF therapy and presents evidence for roles of vascular pruning, hypoxia, and c-Met activation. The results show that simultaneous inhibition of c-Met and VEGF signaling not only slows tumor growth but also reduces invasion and metastasis.

[1]  U. McDermott,et al.  Acquired resistance of non-small cell lung cancer cells to MET kinase inhibition is mediated by a switch to epidermal growth factor receptor dependency. , 2010, Cancer research.

[2]  Masahiro Inoue,et al.  Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. , 2009, Cancer cell.

[3]  N. Sato,et al.  Radiation stimulates HGF receptor/c‐Met expression that leads to amplifying cellular response to HGF stimulation via upregulated receptor tyrosine phosphorylation and MAP kinase activity in pancreatic cancer cells , 2003, International journal of cancer.

[4]  K. Nagashima,et al.  GPR124, an orphan G protein-coupled receptor, is required for CNS-specific vascularization and establishment of the blood–brain barrier , 2011, Proceedings of the National Academy of Sciences.

[5]  J. Christensen,et al.  Enzymatic characterization of c-Met receptor tyrosine kinase oncogenic mutants and kinetic studies with aminopyridine and triazolopyrazine inhibitors. , 2009, Biochemistry.

[6]  R. Cardiff,et al.  Met induces mammary tumors with diverse histologies and is associated with poor outcome and human basal breast cancer , 2009, Proceedings of the National Academy of Sciences.

[7]  T. Nakagawa,et al.  E7050: A dual c‐Met and VEGFR‐2 tyrosine kinase inhibitor promotes tumor regression and prolongs survival in mouse xenograft models , 2010, Cancer science.

[8]  M. Schott,et al.  Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid Cancer , 2012 .

[9]  D. Stolz,et al.  Cross-talk between Epidermal Growth Factor Receptor and c-Met Signal Pathways in Transformed Cells* , 2000, The Journal of Biological Chemistry.

[10]  S. Thorgeirsson,et al.  Beta-cell-specific ablation of the hepatocyte growth factor receptor results in reduced islet size, impaired insulin secretion, and glucose intolerance. , 2005, The American journal of pathology.

[11]  K. Yamaguchi,et al.  Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases. , 2009, Cancer research.

[12]  J. Bishop,et al.  Cellular adherence elicits ligand-independent activation of the Met cell-surface receptor. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[13]  Jie Qi,et al.  Multiple mutations and bypass mechanisms can contribute to development of acquired resistance to MET inhibitors. , 2011, Cancer research.

[14]  D. Smith,et al.  Cabozantinib (XL184) in metastatic castration-resistant prostate cancer (mCRPC): Results from a phase II randomized discontinuation trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  L. Zentilin,et al.  Semaphorin 3A is an endogenous angiogenesis inhibitor that blocks tumor growth and normalizes tumor vasculature in transgenic mouse models. , 2009, The Journal of clinical investigation.

[16]  M. Nieto,et al.  The snail superfamily of zinc-finger transcription factors , 2002, Nature Reviews Molecular Cell Biology.

[17]  John M L Ebos,et al.  Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. , 2009, Cancer cell.

[18]  Gavin Thurston,et al.  Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. , 2004, The American journal of pathology.

[19]  Shinji Yamazaki,et al.  Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma , 2007, Molecular Cancer Therapeutics.

[20]  D. Bottaro,et al.  Targeting the c-Met signaling pathway in cancer. , 2008, Clinical cancer research : an official journal of the American Association for Cancer Research.

[21]  M. Westphal,et al.  Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. , 2000, Neoplasia.

[22]  Karl J. Dykema,et al.  Met induces diverse mammary carcinomas in mice and is associated with human basal breast cancer , 2009, Proceedings of the National Academy of Sciences.

[23]  Gerhard Christofori,et al.  EMT, the cytoskeleton, and cancer cell invasion , 2009, Cancer and Metastasis Reviews.

[24]  S. Thorgeirsson,et al.  β-Cell-Specific Ablation of the Hepatocyte Growth Factor Receptor Results in Reduced Islet Size, Impaired Insulin Secretion, and Glucose Intolerance , 2005 .

[25]  G. Merlino,et al.  Constitutive c-Met signaling through a nonautocrine mechanism promotes metastasis in a transgenic transplantation model. , 2002, Cancer research.

[26]  J. Pouysségur,et al.  Hypoxia signalling in cancer and approaches to enforce tumour regression , 2006, Nature.

[27]  D. Hanahan,et al.  Heritable formation of pancreatic beta-cell tumours in transgenic mice expressing recombinant insulin/simian virus 40 oncogenes. , 1985, Nature.

[28]  L. Trusolino,et al.  MET signalling: principles and functions in development, organ regeneration and cancer , 2010, Nature Reviews Molecular Cell Biology.

[29]  Y. Shyr,et al.  Transforming Growth Factor-β Signaling–Deficient Fibroblasts Enhance Hepatocyte Growth Factor Signaling in Mammary Carcinoma Cells to Promote Scattering and Invasion , 2008, Molecular Cancer Research.

[30]  J. Christensen,et al.  A preclinical review of sunitinib, a multitargeted receptor tyrosine kinase inhibitor with anti-angiogenic and antitumour activities. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[31]  E. Kistner,et al.  c-Met overexpression is a prognostic factor in ovarian cancer and an effective target for inhibition of peritoneal dissemination and invasion. , 2007, Cancer research.

[32]  E. Lengyel,et al.  C‐Met overexpression in node‐positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu , 2005, International journal of cancer.

[33]  Do-Hyun Nam,et al.  Prognostic significance of c‐Met expression in glioblastomas , 2009, Cancer.

[34]  D. Hanahan,et al.  Polymorphic genetic control of tumor invasion in a mouse model of pancreatic neuroendocrine carcinogenesis , 2010, Proceedings of the National Academy of Sciences.

[35]  T. Welling,et al.  c-Met is a marker of pancreatic cancer stem cells and therapeutic target. , 2011, Gastroenterology.

[36]  D. Hanahan,et al.  Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. , 1999, Science.

[37]  L. Ellis,et al.  VEGF-targeted therapy: mechanisms of anti-tumour activity , 2008, Nature Reviews Cancer.

[38]  Yongchang Shi,et al.  Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth , 2011, Molecular Cancer Therapeutics.

[39]  J. Fleming,et al.  Molecular Consequences of Silencing Mutant K-ras in Pancreatic Cancer Cells: Justification for K-ras–Directed Therapy , 2005, Molecular Cancer Research.

[40]  R. Brekken,et al.  Combination of a monoclonal anti‐phosphatidylserine antibody with gemcitabine strongly inhibits the growth and metastasis of orthotopic pancreatic tumors in mice , 2006, International journal of cancer.

[41]  L. Ellis,et al.  Vascular endothelial growth factor is an in vivo survival factor for tumor endothelium in a murine model of colorectal carcinoma liver metastases , 2000, Cancer.

[42]  L. Lin,et al.  Modulation of c-MET proto-oncogene (HGF receptor) mRNA abundance by cytokines and hormones: evidence for rapid decay of the 8 kb c-MET transcript. , 1994, Oncogene.

[43]  K. Yamaguchi,et al.  Preclinical Development Cabozantinib ( XL 184 ) , a Novel MET and VEGFR 2 Inhibitor , Simultaneously Suppresses Metastasis , Angiogenesis , and Tumor Growth , 2011 .

[44]  Z. Han,et al.  Cross‐talk between the VEGF‐A and HGF signalling pathways in endothelial cells , 2009, Biology of the cell.

[45]  A. Dulak,et al.  HGF-independent Potentiation of EGFR Action by c-Met , 2011, Oncogene.

[46]  P. Kelly,et al.  Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival. , 2009, Journal of neurosurgery.

[47]  Morag Park,et al.  Crosstalk in Met receptor oncogenesis. , 2009, Trends in cell biology.

[48]  L. Ferrell,et al.  Activation of the Met Receptor by Cell Attachment Induces and Sustains Hepatocellular Carcinomas in Transgenic Mice , 2001, The Journal of cell biology.

[49]  J. Santibañez,et al.  TGF-β/TGF-β receptor system and its role in physiological and pathological conditions. , 2011, Clinical science.

[50]  P. Comoglio,et al.  Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. , 2003, Cancer cell.

[51]  Bjørn Tore Gjertsen,et al.  Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival , 2009, Proceedings of the National Academy of Sciences.

[52]  References , 1971 .

[53]  T. Ching,et al.  Distinct ligand binding sites in integrin α3β1 regulate matrix adhesion and cell–cell contact , 2003, The Journal of cell biology.

[54]  L. Naldini,et al.  Targeting the tumor and its microenvironment by a dual-function decoy Met receptor. , 2004, Cancer cell.

[55]  J. Minna,et al.  Epidermal growth factor receptor regulates MET levels and invasiveness through hypoxia-inducible factor-1α in non-small cell lung cancer cells , 2010, Oncogene.

[56]  Lance A. Liotta,et al.  Cancer: Out of air is not out of action , 2003, Nature.

[57]  J. Thiery.  Epithelial–mesenchymal transitions in tumour progression , 2002, Nature Reviews Cancer.

[58]  Gerhard Christofori,et al.  A causal role for E-cadherin in the transition from adenoma to carcinoma , 1998, Nature.

[59]  T. Mccauley,et al.  Sequential loss of tumor vessel pericytes and endothelial cells after inhibition of platelet-derived growth factor B by selective aptamer AX102. , 2007, Cancer research.

[60]  E. Schwarz,et al.  The orally bioavailable met inhibitor PF‐2341066 inhibits osteosarcoma growth and osteolysis/matrix production in a xenograft model , 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[61]  Oriol Casanovas,et al.  Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. , 2005, Cancer cell.

[62]  M. Bloomston,et al.  TIMP-1 overexpression in pancreatic cancer attenuates tumor growth, decreases implantation and metastasis, and inhibits angiogenesis. , 2002, The Journal of surgical research.

[63]  Napoleone Ferrara,et al.  Angiogenesis as a therapeutic target , 2005, Nature.

[64]  Gabriele Bergers,et al.  Modes of resistance to anti-angiogenic therapy , 2008, Nature Reviews Cancer.

[65]  I. Kasman,et al.  MetMAb, the one-armed 5D5 anti-c-Met antibody, inhibits orthotopic pancreatic tumor growth and improves survival. , 2007, Cancer research.

[66]  M. Ratain,et al.  Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[67]  P. Comoglio,et al.  The MET receptor tyrosine kinase in invasion and metastasis , 2007, Journal of cellular physiology.

[68]  Alison Murphy,et al.  Inhibition of Transforming Growth Factor β Signaling Reduces Pancreatic Adenocarcinoma Growth and Invasiveness , 2007, Molecular Pharmacology.

[69]  E. Rimm,et al.  Expression of c‐met is a strong independent prognostic factor in breast carcinoma , 1998, Cancer.

[70]  D. Hanahan,et al.  Elevated levels of IGF-1 receptor convey invasive and metastatic capability in a mouse model of pancreatic islet tumorigenesis. , 2002, Cancer cell.

[71]  D. Bottaro,et al.  Targeting the c-Met Signaling Pathway in Cancer , 2006, Clinical Cancer Research.

[72]  W. You,et al.  VEGF and c-Met blockade amplify angiogenesis inhibition in pancreatic islet cancer. , 2011, Cancer research.